BioLineRx (BLRX) Posts Q3 Loss of 1c/ADS

BioLineRx (NASDAQ: BLRX) reported Q3 EPS of ($0.01), $0.16 better than the analyst estimate of ($0.17).

For earnings history and earnings-related data on BioLineRx (BLRX) click here.

You May Also Be Interested In

• McDonald’s said to plan value strategy overhaul to revive US sales growth
• BofA Securities Reiterates Underperform Rating on HubSpot Inc (HUBS)
• Moncler SpA (MONC:IM) (MONRY) PT Lowered to EUR50 at Morgan Stanley